A Study of JMT101 in Patients With Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
DRUG

JMT101

JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

SG001

240 mg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Irinotecan

180mg/m\^2, IV infusion once every two weeks (one treatment cycle is 4 weeks).

DRUG

Regorafenib (Stivarga)

160 mg, taken orally once daily for the first 21 days of each 28-day cycle.

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT06089330 - A Study of JMT101 in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter